Gyre Therapeutics, Inc. Lessee, Operating Lease, Liability, to be Paid, Year Two
Gyre Therapeutics, Inc. (GYRE) had Lessee, Operating Lease, Liability, to be Paid, Year Two of $683.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo · last filed 2026-08-07
- 2026-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Two $683.00K.
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Two $303.00K.
- 2025-09-30: Lessee, Operating Lease, Liability, to be Paid, Year Two $300.00K.
- 2025-06-30: Lessee, Operating Lease, Liability, to be Paid, Year Two $298.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Two |
|---|---|
| 2026-06-30 | $683.00K 10-Q · filed 2026-08-07 |
| 2025-12-31 | $303.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $298.00K 10-Q · filed 2025-08-11 |
| 2025-03-31 | $638.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $631.00K 10-K · filed 2025-03-17 |
| 2024-09-30 | $617.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $598.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $106.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | $103.00K 10-K · filed 2024-03-27 |
| 2021-12-31 | $410.00K 10-K · filed 2022-03-31 |
| 2021-09-30 | $259.00K 10-Q · filed 2021-11-12 |
| 2021-06-30 | $260.00K 10-Q · filed 2021-08-05 |
| 2021-03-31 | $259.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | $762.00K 10-K · filed 2021-03-04 |
| 2020-09-30 | $614.00K 10-Q · filed 2020-11-05 |
| 2020-06-30 | $596.00K 10-Q · filed 2020-08-06 |
| 2020-03-31 | $596.00K 10-Q · filed 2020-05-11 |
| 2019-12-31 | $596.00K 10-K · filed 2020-02-20 |
| 2019-09-30 | $578.00 10-Q · filed 2019-11-07 |
| 2019-06-30 | $578.00 10-Q · filed 2019-08-01 |
| 2019-03-31 | $578.00 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |